Kidney Cancer Research Summit

Lenvima, Keytruda Elicits Greater Responses Than Sutent in Advanced RCC

July 14th 2023, 7:00pm

Responses to treatment with Lenvima plus Keytruda for advanced renal cell carcinoma were present regardless of PD-L1 status.

Insurance Type May Indicate Survival Outcomes in Metastatic RCC

July 13th 2023, 9:00pm

Article

Patients with Medicaid or no insurance may have worse survival outcomes compared with Medicare or private insurance in those with metastatic renal cell carcinoma.

Latest News

Subcutaneous Keytruda Plus Berahyaluronidase Alfa Combo Meets Phase 3 Trial End Points in NSCLC

UGN-102 Shows Promising Treatment Responses in Recurrent Bladder Cancer

Feelings of Gratitude in November as a Colon Cancer Survivor

Aerobic Exercise May Improve Self-Reported Cognitive Function in Breast Cancer

View More Latest News